Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Godfrey, Anna L  [Clear All Filters]
Journal Article
Zhou Y, Shalhoub RN, Rogers SN, Yu S, Gu M, Fabre MAlice, Quiros PM, Diangson A, Deng W, Anand S, et al. Clonal Hematopoiesis Is Not Significantly Associated with Covid-19 Disease Severity. Blood. 2022.
Ryou H, Sirinukunwattana K, Aberdeen A, Grindstaff G, Stolz BJ, Byrne H, Harrington HA, Sousos N, Godfrey AL, Harrison CN, et al. Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients. Leukemia. 2022.
Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, E Baxter J, Massie CE, Papaemmanuil E, Menon S, et al. Effect of Mutation Order on Myeloproliferative Neoplasms. N Engl J Med. 2015;372(7):601-612.
Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, et al. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun. 2015;6:6691.
Godfrey AL, Campbell PJ, Maclean C, Buck G, Cook J, Temple J, Wilkins BS, Wheatley K, Nangalia J, Grinfeld J, et al. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. J Clin Oncol. 2018:JCO2018788414.
Guo J, Walter K, Quiros PM, Gu M, E Baxter J, Danesh J, Di Angelantonio E, Roberts D, Guglielmelli P, Harrison CN, et al. Inherited polygenic effects on common hematological traits influence clonal selection on JAK2 and the development of myeloproliferative neoplasms. Nat Genet. 2024.
Li J, Kent DG, Godfrey AL, Manning H, Nangalia J, Aziz A, Chen E, Saeb-Parsy K, Fink J, Sneade R, et al. JAK2V617F-homozygosity drives a phenotypic switch between myeloproliferative neoplasms in a murine model, but is insufficient to sustain clonal expansion. Blood. 2014.
Fang Z, Fattori GCorbizi, McKerrell T, Boucher RH, Jackson A, Fletcher RS, Forte D, Martin J-E, Fox S, Roberts J, et al. Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis. Nat Commun. 2023;14(1):7725.